NASDAQ:NRSN

Neurosense Therapeutics Stock News

Healthcare > Biotechnology

Buy NRSN

*Your capital is at risk

$0.780

-0.0196 (-2.45%)

At Close: Jun 03, 2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing

02:30pm, Tuesday, 28'th Apr 2026

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50

01:00am, Tuesday, 07'th Apr 2026

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are currently covering the company, Marketbeat Ratings

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

09:20am, Monday, 06'th Apr 2026

Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PR

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

10:02am, Friday, 03'rd Apr 2026

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirem

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

09:20am, Tuesday, 31'st Mar 2026

2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of de

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

09:00am, Tuesday, 24'th Mar 2026

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

08:00am, Wednesday, 18'th Mar 2026

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PR

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

11:33am, Monday, 16'th Mar 2026

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower func

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

11:07am, Monday, 09'th Mar 2026

CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 14.7% – Time to Sell?

03:31am, Thursday, 19'th Feb 2026

Shares of NeuroSense Therapeutics Ltd. (NASDAQ: NRSN - Get Free Report) traded down 14.7% during trading on Wednesday. The stock traded as low as $0.8531 and last traded at $0.8531. 931,449 shares wer

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

09:05am, Wednesday, 18'th Feb 2026

CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by